Key terms

About AMRN

Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. It focuses on the development and commercialization of Vascepa capsules. The company was founded by Geoffrey William Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest AMRN news

Mar 25 8:23am ET Amarin to present research on benefits of VASCEPA/VAZKEPA Mar 08 8:45am ET Largest borrow rate increases among liquid names Mar 05 8:45am ET Largest borrow rate increases among liquid names Mar 01 1:00am ET Amarin Corporation Plc’s New Competition Risk – A Cause for Worry? Feb 29 12:35pm ET Amarin’s Sell Rating Affirmed Amid Declining U.S. Sales and Uncertain International Expansion Feb 29 7:06am ET Amarin reports Q4 EPS 0c, consensus (3c) Feb 29 7:05am ET Options Volatility and Implied Earnings Moves Today, February 29, 2024 Feb 20 8:45am ET Largest borrow rate increases among liquid names Feb 14 8:45am ET Largest borrow rate increases among liquid names Feb 02 8:45am ET Largest borrow rate increases among liquid names Jan 27 4:02am ET Amarin Regains Compliance, Maintains NASDAQ Listing Jan 22 7:34am ET Amarin chairman, CEO issues letter to shareholders Jan 15 12:10am ET Analysts Offer Insights on Healthcare Companies: Shockwave Medical (SWAV), Amarin (AMRN) and Mereo Biopharma Group Plc (MREO) Jan 12 11:36am ET Biotech Alert: Searches spiking for these stocks today Jan 10 8:50pm ET Analysts’ Opinions Are Mixed on These Healthcare Stocks: Tecan Group AG (OtherTCHBF) and Amarin (AMRN) Jan 10 7:04am ET Amarin on track to deliver $40M of annual savings from reduction in force Jan 10 7:04am ET Amarin plans to initiate share repurchase program up to $50M Jan 10 7:03am ET Amarin announces 2024 priorities Jan 10 7:02am ET Amarin sees Q4 revenue $72M-$74M, consensus $62.03M

No recent news articles are available for AMRN

No recent press releases are available for AMRN

AMRN Financials

1-year income & revenue

Key terms

AMRN Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

AMRN Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms